Neutralising antibodies to certolizumab pegol do not appear to impact on efficacy or safety in patients with crohn's disease

被引：0
|
作者：
Nesbitt, A. M. [1 ]
Stephens, S. [2 ]
Bloomfield, R. [3 ]
机构：
[1] UCB, Antibody Biol Div, Slough, Berks, England
[2] UCB, Clin Assay Dept, Slough, Berks, England
[3] UCB, Slough, Berks, England
来源：
GUT | 2008年 / 57卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
372
引用
收藏
页码：A142 / A142
页数：1
相关论文
共 50 条
  • [31] Maintenance therapy with certolizumab pegol for Crohn's disease
    Schreiber, Stefan
    Khaliq-Kareemi, Mani
    Lawrance, Ian C.
    Thomsen, Ole Ostergaard
    Hanauer, Stephen B.
    McColm, Juliet
    Bloomfield, Ralph
    Sandborn, William J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (03): : 239 - 250
  • [32] Certolizumab pegol for induction of remission in Crohn's disease
    Yamazaki, Hajime
    So, Ryuhei
    Matsuoka, Katsuyoshi
    Kobayashi, Taku
    Shinzaki, Shinichiro
    Matsuura, Minoru
    Okabayashi, Shinji
    Kataoka, Yuki
    Tsujimoto, Yasushi
    Furukawa, Toshi A.
    Watanabe, Norio
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2019, (08):
  • [33] Efficacy and Safety of Certolizumab Pegol Induction Therapy in an Unselected Crohn's Disease Population: Results of the FACTS Survey
    Schoepfer, Alain M.
    Vavricka, Stephan R.
    Binek, Janek
    Felley, Christian
    Geyer, Martin
    Manz, Michael
    Rogler, Gerhard
    de Saussure, Philippe
    Sauter, Bernhard
    Seibold, Frank
    Straumann, Alex
    Michetti, Pierre
    INFLAMMATORY BOWEL DISEASES, 2010, 16 (06) : 933 - 938
  • [34] Efficacy of certolizumab pegol in Crohn's disease patients with secondary failure to infliximab is not affected by concommittant medications
    Sandborn, W.
    Vermerie, S.
    Abreu, M.
    D'Haens, G.
    Colombel, J.
    Mitchev, K.
    Jamoul, C.
    Fedorak, R.
    Spehlmann, M.
    Wolf, D.
    Lee, S.
    Rutgeerts, P.
    INFLAMMATORY BOWEL DISEASES, 2009, 15 (12) : S15 - S16
  • [35] Efficacy of Certolizumab Pegol in Crohn's Disease Patients with Secondary Failure to Infliximab Is Not Affected by Concomitant Medications
    Sandborn, William
    Vermeire, Severine
    Abreu, Maria
    D'Haens, Geert
    Colombel, Jean-Frederick
    Mitchev, Krassimir
    Jamoul, Corinne
    Fedorak, Richard
    Spehlmann, Martina
    Wolf, Douglas
    Lee, Scott
    Rutgeerts, Paul
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2009, 104 : S451 - S452
  • [36] Superior efficacy of certolizumab pegol in early Crohn's disease is independent of Crp status
    Schreiber, Stefan
    Hanauer, Stephen B.
    Lichtenstein, Gary R.
    Sandborn, William J.
    GASTROENTEROLOGY, 2007, 132 (04) : A510 - A511
  • [37] Safety Profile of Extraintestinal Manifestations of Crohn's Disease During Treatment With Certolizumab Pegol
    Randall, Charles W.
    Wolf, Douglas C.
    Spearman, Marshall
    Kosutic, Gordana
    Coarse, Jason
    Loftus, Edward V., Jr.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2015, 110 : S780 - S781
  • [38] Efficacy of Certolizumab Pegol in Crohn's Disease: Response to Ford et al.
    Kayhan, Cem
    Pierre-Louis, Bosny
    Sen, David
    Serna, Mylene
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2012, 107 (02): : 321 - 321
  • [39] In patients suffering from Crohn's disease, no cross reaction between antibodies to infliximab and certolizumab pegol was detected
    Nesbitt, Andrew M.
    Vetterlein, Olivia M.
    Kopotsha, Tim M. T.
    Brown, Derek T.
    Stephens, Sue
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2006, 101 (09): : S437 - S438
  • [40] Long-Term Efficacy and Safety of Certolizumab Pegol in an Unselected Crohn's Disease Population: The FACTS III Survey
    Vavricka, Stephan R.
    Spasojevic, Milos
    Rogler, Gerhard
    Schoepfer, Alain M.
    Seibold, Frank
    Borovicka, Jan
    Frei, Pascal
    Zeitz, Jonas
    Greuter, Thomas
    Manser, Christine
    Scharl, Michael
    Misselwitz, Benjamin
    Straumann, Alex
    Michetti, Pierre
    Biedermann, Luc
    DIGESTIVE DISEASES, 2017, 35 (05) : 423 - 432
12345